

Prof. Andrea Riccardo Filippi, MD

Professional Curriculum

PERSONAL INFORMATION

- Born in Turin on September 26, 1972, he resides in Turin, Corso G. Ferraris 2, 10121.
- Married, 2 daughters
- Mobile: 349 4694536, email: andrea.filippi@unipv.it, a.filippi@smatteo.pv.it

PROFESSIONAL ADDRESS

Department of Oncology
University of Milan
Fondazione IRCCS Istituto Nazionale Tumori
Via Venezian 1
20133 Milano, Italy

UNIVERSITY EDUCATION

- Graduated from the Faculty of Medicine, University of Turin in March 1998.
- Specialized in Radiation Oncology at the Faculty of Medicine, University of Turin in November 2002.

FELLOWSHIPS

- 2002: *visiting fellow* in the Department of Radiation Therapy at Stanford University.
- 2002-2003: Fellowship in Radiotherapy/Hematology
- 2007: *visiting fellow* at the Department of Stem Cell Transplantation, Stanford University, USA
- 2009: *visiting fellow* at Institut Gustave Roussy, Paris,

CURRENT POSITION

Associate Professor in Radiation Oncology, University of Milan and Head of Department of Radiotherapy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

NATIONAL SCIENTIFIC QUALIFICATION

- *Awarded the National Scientific Qualification for Professor of II stratum, Disciplinary Scientific Area MED/36, Diagnostic Imaging and Radiotherapy, concurrent area 06/I1, in the 2013 session (validity until 26.1.2025)*
- *Awarded the National Scientific Qualification for Professor of Band I, Disciplinary Scientific Area MED/36, Diagnostic Imaging and Radiotherapy, Competitive Area 06/I1, in the 2019 session (validity until 5/15/2029)*

PROFESSIONAL CAREER

Prof. Filippi served in the Department of Radiotherapy of the Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino from August 2004 until December 2011 as a Level I Medical Director.

- He has been Assistant Professor at the University of Turin and Medical Director in Radiotherapy in agreement with SSN until May 2016 at the same University Hospital.
- From May 2016 to March 2018, he was Assistant Professor and Head of the Radiotherapy Unit of the Azienda Ospedaliero Universitaria S. Luigi Gonzaga of Orbassano (Turin).
- Since March 2018, he has been Chair of the Radiation Oncology Department at the IRCCS Policlinico San Matteo Foundation in Pavia, Italy.
- Since December 1st, 2023, he is Associate Professor in Radiation Oncology at the University of Milan and Head of Department of Radiotherapy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

RESEARCH ACTIVITIES

Areas of scholarly activity have been and are in the clinical and technical aspects of radiotherapy treatment of malignant neoplasms, with special reference to pulmonary neoplasms.

Specific research avenues can be identified in the area of early stage and oligometastatic lung cancer (clinical development of the applications of stereotactic radiotherapy), and in the development of combinations of radiotherapy and immunotherapy in lung cancer, particularly for unresectable stage III.

INTERNATIONAL SCIENTIFIC SOCIETIES/RESEARCH GROUPS

He is a member of the following Scientific Societies:

- International Association for the Study of Lung Cancer (IASLC)
- Italian Association of Radiation Therapy Oncology (AIRO)
- European Society for Radiotherapy and Oncology (ESTRO)
- European Society for Medical Oncology (ESMO)
- European Thoracic Oncology Platform (ETOP)
- EORTC Lung Cancer Group

ROLES IN SCIENTIFIC SOCIETIES

- 2009-2012: coordinator of the Youth Group of the Italian Society of Radiation Oncology Therapy
- 2012-2015: member of the Young Task Force of the European Society of Radiotherapy and Oncology (ESTRO)
- 2014-2015: member of the Clinical Committee of the European Society of Radiotherapy and Oncology (ESTRO)
- 2016-2018: member of the Scientific Committee of the Italian Society of Radiotherapy and Oncology (AIRO)
- Track Committee Member for "Radiotherapy," 2022 World Lung Cancer Conference
- Scientific Advisory Group (clinical) for ESTRO 2023 Annual Meeting
- Scientific Advisory Group (clinical) for ESTRO 2024 Annual Meeting
- College of the European Society of Oncology Faculty Member (2022-present)
- European Society of Oncology Mentorship Program Member (2022-present)
- Member of the Advanced Radiotherapy Committee , IASLC
- Core Member of the ESTRO Focus Group on RT and systemic therapies

RESEARCH ORGANIZATIONS

Since December 2021, he has been a member of the Scientific Committee of ICAM (International Centre for Advanced Computing in Medicine), University of Pavia and University of Italian Switzerland.

SCIENTIFIC JOURNALS

He is Associate Editor for *Radiation Oncology* and for *Frontiers in Oncology*.

He is also a scientific reviewer for:

- *Radiotherapy and Oncology*
- *International Journal of Radiation Oncology, Biology and Physics*
- *Frontiers in Oncology*
- *British Journal of Hematology*
- *British Journal of Radiology*
- *Lung Cancer*
- *Clinical Lung Cancer*
- *Journal of Thoracic Oncology*
- *Annals of Oncology*

INTERNATIONAL RESEARCH PROJECTS

He is a reviewer for *INCa* (The French National Cancer Institute), the *Auckland Medical Research Foundation* and *Kom Op Tegen Kanker* (National Cancer Research Program, The Netherlands).

CLINICAL STUDIES

Prof. Filippi is Principal Investigator of the following clinical trials:

- **DUART**: A phase II study of durvalumab following radiotherapy in patients with unresectable, Stage III NSCLC ineligible for chemotherapy. International Study Coordinator/International PI. Sponsor: ASTRA ZENECA.
- **DEDALUS**: An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable NSCLC. Academic study, sponsor: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (externally supported by ASTRA ZENECA)
- **BLUE SKY RADIOMICS**: Observational Study on Computed Tomography as an Image-based Predictive Marker of response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC). Academic study, sponsor: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- **GAZEBO**: An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early-stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi (co-PI with prof. A. Pulsoni). Academic study, sponsor Fondazione Italiana Linfomi (externally supported by Hofmann-La Roche Global, Switzerland).

He is a member of the International Scientific Committee of the studies:

- **RAFTING:** *Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles.* (Sponsor: Medical University of Gdańsk & Polish Lymphoma Research Group (PLRG), externally supported by Bristol Myeras Squibb Global; PI: prof. Andrea Gallamini, Nice, France)
- **PACIFIC-R:** *Real World First retrospective real-world data on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program after chemoradiotherapy.* (Sponsor: Astra Zeneca Global, UK).
- **MDT-BRIDGE:** *Non-randomized phase 2 GMA study of neo-adjuvant durvalumab + CT in early-stage NSCLC followed by surgery or CRT with adjuvant durvalumab* (Sponsor: Astra Zeneca Global, UK).

National Coordination/Local PI:

- Local PI and Italian coordinator for **PACIFIC-9 study:** A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)
- Local PI: **EORTC PrimaLUNG 1901-LCG:** PRophylactic cerebral irradiation or active magnetic resonance imaging surveillance in small-cell lung cancer patients (sponsor: EORTC)
- Local PI: **MK-7684A-006/KEYVIBE-006:** Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006). Sponsor: Merck Sharp and Dome (MSD).
- Local PI: **The Impact of COVID-19 on NSCLC Treatment:** A multi-site, international observational study to understand the impact of the COVID-19 pandemic on the treatment of patients with Stage III unresectable non-small cell lung cancer (NSCLC) (Sponsor ASTRA ZENECA).

OTHER TITLES

Coordinator of the Project "*RADIONET: a proposal for a digital network of Oncology Radiotherapy in Lombardy,*" selected among the finalists of the PROMETEO Project, promoted by FederatedInnovation@MIND and CARIPLO Factory, Milan, Italy.

PUBLICATIONS

He is author/co-author of 160 articles in "extenso" in indexed journals (PubMed, Scopus).
Scopus H-index: 30.

ORCID: <https://orcid.org/my-orcid?orcid=0000-0001-7159-7869>

Twitter/X: @AndrearcFili

Milan, January 1st 2024